The invention relates to the use of a compound comprising the following amino acid sequence X.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6, wherein X.sub.1 is an amino acid, except of C, X.sub.2 is an amino acid, except of C, X.sub.3 is an amino acid, except of C, X.sub.4 is an amino acid, except of C, X.sub.5 is an amino acid, except of C, X.sub.6 is an amino acid, except of C, and wherein X.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6 is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal A.beta.42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal A.beta.42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease.

 
Web www.patentalert.com

< Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas

< Compositions and methods of using Alpha-fetoprotein growth inhibitory peptides

> Methods and compositions for treating pain

> Methods and compositions for therapeutic treatment
~ 00263